Beyond oxidative stress: an immunologist's guide to reactive oxygen species

Carl Nathan[1,2] and Amy Cunningham-Bussel[1,2]

Abstract | Reactive oxygen species (ROS) react preferentially with certain atoms to modulate functions ranging from cell homeostasis to cell death. Molecular actions include both inhibition and activation of proteins, mutagenesis of DNA and activation of gene transcription. Cellular actions include promotion or suppression of inflammation, immunity and carcinogenesis. ROS help the host to compete against microorganisms and are also involved in intermicrobial competition. ROS chemistry and their pleiotropy make them difficult to localize, to quantify and to manipulate — challenges we must overcome to translate ROS biology into medical advances.

The term 'reactive oxygen species' (ROS) includes super-oxide, hydrogen peroxide, singlet oxygen, ozone, hypo-halous acids and organic peroxides[1]. ROS participate in phenomena that traverse all of biology, and their study has burgeoned for more than a century (TIMELINE). ROS are difficult to distinguish from each other by specific assays and are challenging to quantify. The diversity of their enzymatic sources has only recently become apparent, and tools for the identification of their subcellular localization are only now emerging. Many of their effects can be opposed to one another — for example, they can both promote and prevent cell death, inflammation or ageing.

Further complicating their study, ROS are not the only class of endogenous small, reactive signalling molecules; other classes include reactive nitrogen species (RNS), such as nitric oxide (NO•) and NO_2•; hydrogen sulphide (H_2S) or its anion HS−; and carbon monoxide (CO). These other reactive molecules can have properties that both overlap with and are distinct from those of ROS. Scientists who study ROS and RNS organize separate conferences, but the molecules themselves interact and affect the production and targets of one another[3–5].

Most medical interventions that target ROS have failed (discussed in REF. 6). This can be interpreted to mean that ROS have an unimportant role in pathophysiology; however, it might also be that the interventions tested were not based on an adequate understanding of ROS biochemistry and biology, which is still emerging[7]. Moreover, among immunologists who consider specificity the hallmark of the discipline, some labour under the misconception that

ROS are nonspecific, and a few cling to the view that only phagocytes produce ROS and that the only function of ROS is to kill pathogens and host cells.

Thus, it is no surprise that until recently it was rare to find a diagram of signal transduction or a systems biology analysis that took ROS into account. However, in the past few years, many of the obstacles mentioned above have been overcome. Scientists are now aware that ROS routinely arise in most cells from defined sources, that they affect multiple targets in specific ways and that they exert considerable influence over cell function.

In this Review, we describe ROS in terms of their regulation, targets and actions. Because the topic is vast, our approach is illustrative rather than comprehensive. Given the conservation of ROS biology, we draw lessons from diverse fields to lend perspective to the role of ROS in immunology.

ROS homeostasis

Many authors state that 'oxidative stress' occurs when the production of ROS exceeds their catabolism. However, the term stress is an imprecise reference to a restricted range of ROS signalling that runs from adaptive to maladaptive (FIG. 1) and has a major role in cell and organismal biology[1,8–10] (FIG. 1). Thus, oxidative stress is by no means a description of, nor a synonym for, the biology of ROS.

Sources of ROS. Endogenous sources of ROS in mammals (BOX 1) include seven isoforms of NADPH oxidases (NOXs)[10,11] that are differentially expressed in diverse cells and species[12]; the mitochondrial respiratory chain;

[1]Department of Microbiology and Immunology, Weill Cornell Medical College, Cornell University, New York, New York 10065, USA.
[2]Graduate programme in Immunology and Microbial Pathogenesis, Weill Graduate School of Medical Sciences, Cornell University, New York, New York 10065, USA.
Correspondence to C.N.
e-mail:
cnathan@med.cornell.edu
doi:10.1038/nri3423

Timeline | A sampling of milestones in ROS biology*

Warburg discovers increased consumption of oxygen by sea urchin eggs following fertilization[134]. The biological importance only becomes apparent in 1978

Fleming discovers that *Penicillium notatum* releases an antibacterial product. The search for other antibiotics from fungi is hindered by contamination with fungal glucose oxidase, which produces H_2O_2 that contributes additional antibiotic activity[136]. It is discovered 78 years later that many antibiotics themselves, including β-lactams such as penicillin, partly work by causing bacteria to generate ROS

Discovery of superoxide dismutase from diverse tissues indicates production of superoxide[139]

The hypothesis that some cells can produce superoxide is confirmed. These cells are found to be PMNs[140]

PMNs from patients with CGD, who have increased susceptibility to infection, are found to produce little or no superoxide. This suggests the first biological function for ROS: the killing of pathogens. Production of ROS represents the first defined host defence mechanism[141]

1908   1928   1929   1959   1961   1969   1973   1974   1975

Fungal glucose oxidase is the first enzyme found to produce ROS, namely H_2O_2 (REF. 135)

Phagocytosing PMNs are found to consume large amounts of oxygen by a non-mitochondrial process[137]

The first ROS identified as being produced by a mammalian cell is H_2O_2 in phagocytosing PMNs[138], which explains their increased oxygen consumption

Non-activated macrophages are found to relieve the dependence of lymphoid cells on exogenous thiols for their survival *in vitro*. By contrast, immunologically activated macrophages, which were soon found to produce ROS (see 1977), do not fulfil this accessory cell function. The lack of trophic support by activated macrophages contributes to their apparent ability to kill lymphoma cells[90]

CGD, chronic granulomatous disease; FDA, US Food and Drug Administration; IFNγ, interferon-γ; PMN, polymorphonuclear leukocyte; ROS, reactive oxygen species. *This Timeline is an incomplete history, with only limited citations.

---

the flavoenzyme ERO1 in the endoplasmic reticulum; xanthine oxidase; lipoxygenases; cyclooxygenases; cytochrome P450s; a flavin-dependent demethylase; oxidases for polyamines and amino acids; and nitric oxide synthases. Free copper ions or iron ions that are released from iron–sulphur clusters, haem groups or metal storage proteins can convert $O_2^{\bullet-}$ and/or H_2O_2 to $OH^{\bullet}$ (REF. 13).

Regulation of ROS production. Several checkpoints restrict ROS production by the NOXs to times and locations that are appropriate for cellular functions. NOXs are transmembrane flavocytochrome proteins, the cytosolic domains of which transfer an electron from NADPH to a FAD cofactor. From there, the electron is passed to a haem group, which donates it to O_2 on the extracellular side of the membrane, generating $O_2^{\bullet-}$. One control step in this process is the loading of the apoprotein with the flavin cofactor[14]. In another level of regulation, Ca^{2+} signalling, phosphorylation cascades and the activation of small G proteins control the recruitment of accessory proteins from the cytosol to join the flavocytochrome at the membrane, forming the functional NOX complex[8]. NOXs are activated following the activation of receptors by ligands such as insulin, platelet-derived


Figure 1 | **The broad range of ROS signalling is influenced by ROS production and catabolism, and by cellular adaptation.** Restriction of reactive oxygen species (ROS) production to appropriate subcellular locations, times, levels, molecular species and for appropriate durations allows ROS to contribute to homeostasis and physiological cell activation. For example, brief pulses of H_2O_2 production at the plasma membrane or at the endosomal membrane mediate signalling in response to the engagement of receptors with cytokines, microbial products or antigens (left-hand side). When ROS production escapes these restrictions — for example, when there are high levels or sustained production of hydroxyl radicals — macromolecules are damaged ('oxidative stress'). ROS-mediated damage can often be reversed by repair, replacement, degradation or sequestration of the damaged macromolecules (middle). However, damage that exceeds the capacity of the cell for these responses can lead to cell death (right-hand side). When damage to DNA results in mutagenesis without irreparable double-strand breakage, and when damage to other macromolecules is repaired, the consequence can be malignant transformation rather than death of the cell (right-hand side).

Iron–sulphur clusters
Prosthetic groups that are required for the function of some enzymes. In iron–sulphur clusters two, three or four atoms of iron are attached to the protein through two or four sulphydryl groups.

Macrophages are identified as the second mammalian cell type to produce ROS. ROS production increases markedly following immunological activation and this is associated with enhanced antimicrobial activity[142]

Leukocyte-derived H_2O_2 is confirmed to kill many kinds of pathogens, a process that is facilitated by myeloperoxidase[145]

IFNγ is defined as a major inducer of ROS production and antimicrobial function in mouse macrophages[146]

Prophylaxis with IFNγ is tested in children with CGD and found to markedly reduce the incidence of infections[149]. The FDA soon approves recombinant IFNγ for clinical use[66]

Human tumour cell lines are found to produce H_2O_2 spontaneously at rates comparable to PMNs[110]. These were the first mammalian, non-myeloid cells found to produce large amounts of ROS. It is hypothesized that tumour-derived ROS contribute to oncogenesis and cancer progression

Additional isoforms of ROS-producing NADPH oxidases are identified in non-myeloid cells and implicated in malignant transformation[150]

1977   1978   1980   1983   1986   1988   1991   1999   2007

A non-myeloid cell is identified that undergoes an H_2O_2-producing respiratory burst like that of PMN and macrophages: the sea urchin egg undergoing fertilization. Besides explaining Warburg's 1908 observation, this shows a second biological function of ROS: oxidative crosslinking of tyrosine residues to produce the fertilization membrane, preventing polyspermy[143]

A superoxide-producing, cytochrome-containing activity is discovered in neutrophil membranes[144]

IFNγ is defined as a principal inducer of ROS production and antimicrobial function in humans[147]

A subunit of the superoxide-producing NADPH oxidase enzyme discovered in 1978 is cloned on the basis of its being mutated in patients with CGD. This is the first enzyme identified the function of which seems to be the *de novo* generation of ROS, as opposed to making ROS as a by-product or turning one ROS into another[148]

Antibiotics with diverse primary targets are found to kill bacteria partly by inducing them to produce ROS[129]. Thus, a major form of natural host defence against infection and a principal form of medical treatment for infection converge on the generation of ROS

growth factor, nerve growth factor, fibroblast growth factor, chemokines that bind G protein-coupled receptors, tumour necrosis factor (TNF), granulocyte–macrophage colony-stimulating factor (GM-CSF), angiotensin, sphingosine-1-phosphate, lysophospholipids, complement component 5a (C5a) and leukotriene B4 (LTB4), as well as by cell adhesion and by phagocytosis[1,8]. The mechanisms linking receptor interaction to NOX activation are an important research area in immune signalling.

ROS production by mitochondria is regulated by diverse factors, including RNS, mammalian target of rapamycin (mTOR), p53, SHC-transforming protein 1 (SHC1), reactive oxygen species modulator 1 (ROMO1), B cell lymphoma 2 (BCL-2) family members[8] and uncoupling proteins[15]. Another factor that promotes mitochondrial ROS generation is hypoxia (discussed below).

Nitric oxide synthases (NOS) can produce ROS when concentrations of their cofactor tetrahydrobiopterin or their cosubstrate L-arginine are limiting. For example, following L-arginine depletion by L-arginase, NOS donate some of their NADPH-derived electrons to O_2 rather than passing all the electrons to the guanidino nitrogens of arginine, generating both $O_2^{•-}$ and $NO^•$. These species react with each other to produce peroxynitrite ($OONO^-$), which decomposes to generate the strong oxidants $OH^•$ and $NO_2^•$ (REF. 16), and can oxidize redox-sensitive cysteines 10^3-fold faster than peroxide[17].

Transcriptional networks control proteins that sense and regulate the uptake and the storage of redox-active metal ions[13]. In addition, other mechanisms that affect the intracellular levels of ROS include the export of xenobiotics that generate ROS[13] and the export of ROS themselves into neighbouring cells through connexin channels[18].

Uncoupling proteins
Proteins in the mitochondrial inner membrane that can divert the proton gradient away from the formation of ATP, resulting in the generation of heat instead.

Xenobiotics
Small chemical compounds that enter an organism unnaturally, such as drugs or pollutants.

Catabolism of ROS. Until recently, the antioxidant systems of a cell were thought to be superoxide dismutases, catalases and the enzymes of the glutathione redox cycle, which couples the reduction of peroxide to the oxidation and the regeneration of reduced glutathione. Many additional physiologically important ROS-regulating enzymes are now recognized, among them thioredoxins, thioredoxin reductases[19], peroxiredoxins (which also function as peroxynitrite reductases) and methionine sulphoxide reductases[8,20,21]. Moreover, recent studies have increased our understanding of glutathione homeostasis. For example, the level of reduced glutathione is preserved in yeast not only through the action of glutathione reductase, but also through the actions of thioredoxin reductase and glutaredoxin, and the export of oxidized glutathione into the vacuole[22].

Pyruvate kinase, an enzyme involved in glycolysis and gluconeogenesis, is crucial in the negative feedback regulation of ROS. When cells metabolize glucose, ROS inhibit pyruvate kinase by oxidizing Cys358. The resulting inhibition of glycolysis directs carbon flux into the pentose phosphate pathway. This increases the production of NADPH and sustains the reduction of oxidized glutathione and thioredoxin, returning ROS to homeostatic levels[23].

In addition, many small molecules that react with ROS non-enzymatically can be recycled or replenished, giving them a ROS-buffering capacity. These include ascorbate and the α-ketoacids of central carbon metabolism, such as pyruvate, α-ketoglutarate and oxaloacetate[24] (BOX 1). Just as some molecules that are better known for other functions can also function as antioxidants, so molecules that are mainly known as antioxidants can have other functions. For example, when released from cells, thioredoxin is a potent chemoattractant[25] and peroxiredoxins can trigger inflammation[26].

Box 1 | **Sources of ROS and mediators of their catabolism**

Exogenous sources of ROS
- Smoke
- Air pollutants
- Ultraviolet radiation
- γ-irradiation
- Several drugs

Endogenous sources of ROS
- NADPH oxidases
- Mitochondria
- ER flavoenzyme ERO1
- Xanthine oxidase
- Lipoxygenases
- Cyclooxygenases
- Cytochrome P450 enzymes
- Flavin-dependent demethylase
- Polyamine and amino acid oxidases
- Nitric oxide synthases
- Free iron or copper ions
- Haem groups
- Metal storage proteins

Catabolism by antioxidant systems
- Superoxide dismutases
- Catalases
- Glutathione peroxidases
- Glutathione reductase
- Thioredoxins
- Thioredoxin reductases
- Methionine sulphoxide reductases
- Peroxiredoxins or peroxynitrite reductases

Catabolism by small molecules that react with ROS non-enzymatically
- Ascorbate
- Pyruvate
- α-ketoglutarate
- Oxaloacetate

ER, endoplasmic reticulum; ROS, reactive oxygen species. Sources reviewed in REFS 10–12.

Repair of ROS-mediated damage. Cells maintain homeostasis despite ROS production not only by catabolizing ROS but also by repairing oxidative injury. For example, ROS can oxidize the sulphurs that hold the iron atoms in the iron–sulphur clusters. As a result, iron atoms are lost. The apoprotein then loses its original function and might have to be re-synthesized for a new iron–sulphur cluster to be attached. DNA oxidation by ROS activates the nucleotide excision repair and base excision repair pathways[13].

Some oxidative damage cannot be repaired, such as the formation of carbonyl groups on amino acid side chains in proteins. This results in cells degrading irreversibly oxidized macromolecules using the proteasome[27] or autophagosomes[28]. Some macromolecules might be so extensively oxidized that they can be neither repaired nor degraded; cells might respond by sequestering these macromolecules with chaperones. Thus, it is not surprising that a genetic screen of viable deletion strains of *Saccharomyces cerevisiae* for hypersensitivity to ROS identified 456 genes[29]. Many of these genes encoded proteins with additional functions to catabolism of ROS, repair of ROS-dependent damage and the other mechanisms discussed above.

The fact that regulators of ROS are encoded by such a large proportion of the genome and are distributed across so many functional classes reflects the widespread functional effects of ROS. It seems unlikely that evolution selected for fitness by ascribing such a widespread role to molecules that react nonspecifically. We argue below that the biological effects of ROS are in fact highly specific.

Targets of ROS

Atomic targets. ROS display a type of specificity that is atomic rather than molecular: ROS react covalently, often reversibly, with only certain atomic elements in macromolecules, and with only a subset of those atoms[30]

(FIG. 2). Therefore, ROS only seem to react nonspecifically if we limit our ideas of specificity in signalling to molecular 'handshakes' that depend on complementarity, as in the case of insulin binding to its receptor. Such handshakes are well suited to the transmission of a signal along a discrete pathway. By contrast, reactions of ROS with specific atoms that are present in many macromolecules might transmit signals to multiple pathways at once. Depending on the origin and level of ROS, this might occur in discrete subcellular locations or across a large proportion of the cell. ROS that are produced by a local source in small enough amounts to be confined to a restricted subcellular location can function as a rheostat for discrete signalling pathways in that location. ROS that are produced in large enough amounts to diffuse across more of the cell can function as coordinators of global signalling in the cell. After ROS have accumulated to a certain level, their activating effects might give way to inhibitory effects. As a result, the diverse signalling pathways that are simultaneously regulated by cellular ROS levels are associated with the metabolic state of the cell[30].

Consistent with the idea of 'atomic specificity', one of the atoms with which ROS most often reversibly reacts in cell signalling — sulphur — is one of the least abundant atoms in biological macromolecules. Even then, ROS do not react with all sulphur atoms, but mostly with a subset of sulphur atoms in the side chains of cysteine or methionine residues in peptides or proteins. Many of the most ROS-reactive cysteines in proteins are located in environments that are conducive to the participation of the thiolate in active site chemistry. The reactivity of specific cysteinyl thiols is partly influenced by neighbouring amino acid side chains that confer an acidic dissociation constant (low pKa), but additional factors are also involved that remain to be identified[31]. Much remains to be learned about this important form of intracellular signalling[32].

Molecular targets: proteins. A partial list of proteins that have been reported to be physiologically regulated by ROS includes tyrosine and serine/threonine phosphatases, such as phosphatase and tensin homologue (PTEN)[33]; tyrosine and serine/threonine kinases, such as epidermal growth factor receptor[34], protein kinase B[35], ataxia-telangiectasia mutated (ATM) kinase[36], calmodulin-dependent kinase II[37] and protein kinase G-Iα[38]; zinc-finger proteins[39]; other transcription factors, including those of the forkhead box O (FOXO) family[40]; histone deacetylases[41]; signal-regulating binding proteins, such as heat-shock proteins[41]; caspases[41]; metalloproteinases[42]; protease inhibitors, such as α1-antitrypsin[43], α2-macroglobulin[44] and secretory leukocyte protease inhibitor[45]; metabolic enzymes; prolyl hydroxylase[46] and glucose uptake regulator[47], which both depend on α-ketoglutarate as a cofactor; GTP cyclohydrolase[48]; guanylyl cyclase[49]; and ion channels, such as the ryanodine receptor[50].

An important role of ROS in signal transduction is to transiently oxidize the cysteine sulphydryl that contributes to the active site of most phosphatases. The phosphorylation that follows the binding of a ligand to its receptor is usually attributed to the activation of a kinase,

Acidic dissociation constant (pKa). The equilibrium constant for the dissociation of an acid into its conjugate base and hydrogen ion, expressed as the negative logarithm. The lower the pKa of a sulphydryl group, the greater the likelihood that the sulphur will be anionic at ambient pH.

but can also be the result of a burst of ROS formation and the transient inactivation of cognate phosphatases. Proteome-wide assessment has shown that ROS regulation of phosphatases, and hence of phosphorylation, is widespread[51].

In other proteins, ROS sensing by cysteine residues can provide feedback control to regulate the levels of ROS. For example, the intermolecular oxidation of conserved cysteines in the transcription factor FOXO4 allows for the binding of this protein to the p300/CBP acetylase, which leads to lysine acetylation of FOXO4. Such a phenomenon might be related to the ROS-dependent transcriptional induction of manganese superoxide dismutase, catalase, peroxiredoxin and sulphiredoxin, and to the reduction in levels of ROS[40,52]. Similarly, oxidation of important cysteine residues in ATM kinase promotes glucose flux through the pentose phosphate shunt, increasing the levels of NADPH. NADPH is the physiological reductant for oxidized glutathione and thioredoxin, and thus, the ultimate reductant for many ROS-catabolizing enzymes, such as glutathione reductase, peroxiredoxins and methionine sulphoxide reductases[53]. Regulation of ROS seems to be important for the functions of ATM in haematopoiesis[54] and neoangiogenesis[55].

A main function of ROS is their contribution to the activation of transcription by several mechanisms. For example, the bacterial transcription factor SoxR is activated by the superoxide anion, which interacts with the iron–sulphur redox centre of SoxR, whereas another transcription factor, OxyR, is activated by H_2O_2, which oxidizes the cysteinyl thiol of OxyR. Both events lead to the expression of antioxidant enzymes[56]. Moreover, ROS-facilitated protein phosphorylation can lead to the kinase-mediated activation of a transcription factor such as JUN, or to the translocation to the nucleus of a cytosolic transcription factor such as nuclear factor-κB (NF-κB) following the kinase-triggered ubiquitylation and subsequent degradation of its inhibitor (FIG. 3).

ROS can also promote transcription by increasing the accumulation of transcription factors via inhibition of their degradation. For example, increased production of ROS by hypoxic mitochondria (FIG. 4) has an important role in preventing the degradation of hypoxia-inducible factor 1α (HIF1α), which is the main transcription factor that cells use to adapt to the hypoxic state[57–59]. In turn, HIF1α mediates hypoxic transition to glycolytic metabolism, reducing electron flow through mitochondria and reducing the associated production of ROS. Thus, the generation of reactive oxygen intermediates (ROIs; a subset of ROS) under hypoxic conditions should not be viewed as a wasteful process carried out by a poorly evolved system, but rather as an elegant network, through which the reduction in the availability of a crucial molecule triggers transcriptional adaptation.

Molecular targets: DNA. Mitochondrial ROS can promote transcription by oxidizing DNA itself, rather than by oxidizing DNA-binding regulatory proteins (FIG. 5a). For example, ROS that are produced by hypoxic mitochondria oxidize specific bases in the promoter


Figure 2 | **ROS and their atomic specificity.** During the reduction of oxygen to water, sequential one-electron reductions can produce reactive oxygen intermediates (ROIs) — superoxide, hydrogen peroxide and hydroxyl radicals — along with singlet oxygen and ozone. ROIs comprise a subset of reactive oxygen species (ROS). Additional ROS are the hypochlorous (HOCl), hypobromous (HOBr) and hypoiodous acids (HOI) that arise when peroxidases catalyse the oxidation of halides by H_2O_2, as well as important products of the reaction of ROS with other molecules that retain strong oxidizing potential, such as lipid peroxides (included as ROOH in the figure). ROS at low levels tend to react reversibly with a limited number of atoms — for example, selenium or sulphur atoms in a subset of cysteine and methionine residues — conferring atomic specificity in reactions involving diverse macromolecules. At higher levels ROS are likely to react irreversibly with certain iron and carbon atoms. e⁻, electron.

of vascular endothelial growth factor (*VEGF*). This enhances binding of HIF1α to the *VEGF* promoter[60]. Evidence for the physiological relevance of this response comes from the observation in pulmonary artery endothelial cells that hypoxia triggers dynein-dependent movement of mitochondria along microtubules so that the mitochondria cluster around the nucleus. As a result, mitochondrial-dependent ROS promote oxidative modifications of, and HIF1α binding to, the *VEGF* promoter[61]. Thus, ROS are physiological mediators in signalling between mitochondria and the nucleus[9].

In another example of gene regulation through DNA oxidation (FIG. 5b), transcriptional activation by the oestrogen receptor, the androgen receptor, the retinoic acid receptor, the thyroxin receptor and activator protein 1 all require topoisomerase IIb-mediated, site-specific DNA breaks in target gene-regulatory regions[62]. ROS are involved in the formation of these breaks. The oestrogen receptor-activated flavin-dependent lysine-specific histone demethylase 1 (LSD1; also known as KDM1A) produces H_2O_2 (REF. 63). This locally produced H_2O_2 oxidizes bases in target gene-regulatory regions, forming 8-oxoguanine. 8-oxoguanine recruits 8-oxoguanine DNA glycosylase 1 (OGG1), which causes single-stranded DNA breaks. These breaks recruit topoisomerase IIb, which bends DNA while repairing the lesion, thereby enabling the transcription initiation complex to access the targeted promoters[63]. The same process seems to be required for MYC-mediated transcription[64].

Figure 3 | Examples of transcriptional regulation by ROS acting at the plasma membrane or in the cytosol.
Activation of tumour necrosis factor receptor (TNFR) triggers reactive oxygen species (ROS) production, which enhances the phosphorylation (P) of inhibitor of NF-κB (IκB), probably through the oxidative inhibition of a phosphatase. This leads to the ubiquitylation (Ub) of IκB and its subsequent degradation by the proteasome. Nuclear factor-κB (NF-κB) is then released and translocates to the nucleus to initiate transcription. ROS production can also trigger oxidative glutathionylation of NF-κB at its redox sensitive cysteine, which reduces its DNA binding affinity[133]. Under normoxia, prolyl hydroxylases (PHs) hydroxylate hypoxia-inducible factor 1α (HIF1α), which allows it to be recognized by the E3 ligase von Hippel–Lindau tumour-suppressor protein (VHL) and promotes its degradation by the proteasome. Under hypoxia there is increased production of ROS (FIG. 4), which inhibits prolyl hydroxylases, leading to the accumulation of HIF1α. HIF1α then translocates to the nucleus to mediate gene transcription. ROS production by NADPH oxidases (NOXs) following receptor activation by specific ligands, for example, epidermal growth factor receptor (EGFR), inhibits protein tyrosine phosphatases (PTPs), which promotes the phosphorylation of tyrosine kinases (TKs) and the subsequent signal transduction. By contrast, ataxia-telangiectasia mutated (ATM) kinase is activated directly by ROS, through disulphide bond-mediated homodimerization, which leads to the phosphorylation of heat shock protein 27 (HSP27) and the subsequent activation of glucose-6-phosphate-dehydrogenase (G6PD). The resulting increase in NADPH levels contributes to the maintenance of cellular redox homeostasis. ROS-mediated disulphide bonding can also lead to heterodimerization, as seen between forkhead box O (FOXO) transcription factors and p300/CBP acetyltransferase, which leads to the acetylation of FOXO proteins and the activation of specific gene transcription. ERK, extracellular signal-regulated kinase.

Thus, ROS arising from NOXs at the plasma, endo-somal and phagolysosomal membranes, and from mito-chondria in the cytosol, can influence transcription by regulating the phosphorylation of transcription factors; whereas ROS arising from perinuclear mitochondria or from a nuclear flavoenzyme can participate in transcriptional control by targeting DNA directly. This recent understanding of ROS–DNA interactions complements the long-standing recognition of the mutagenic potential of ROS.

Effects of ROS in the immune system
In the immune system, ROS are neither unique products of one subset of cells, such as phagocytes, nor do they have one action, such as to kill other cells. Instead, ROS have a physiological role in signalling that probably extends to every cell type in immunology. As with any signalling mechanism, ROS can become cytotoxic if the signal is too strong, if it lasts too long or if it arises at the wrong time or place.

ROS in innate immunity. The first functional role ascribed to the production of ROS by mammalian cells was the killing of microorganisms by phagocytes (TIMELINE). This was confirmed by the discovery that individuals with chronic granulomatous disease (CGD), a disorder characterized by heightened susceptibility to infection, have disease-causing mutations in NOX2, the main source of ROS in polymorphonuclear leukocytes (PMNs) and mononuclear phagocytes.

Figure 4 | **Regulation of HIF1α by mitochondrial ROS production during hypoxia.** In the presence of O_2 and its cofactor α-ketoglutarate (αKG), HIF-prolyl hydroxylase 2 (HIF-PH2) hydroxylates two proline residues in hypoxia-inducible factor 1α (HIF1α). Hydroxylated HIF1α is then ubiquitylated (Ub) by the E3 ligase von Hippel–Lindau tumour-suppressor protein (VHL) and is subsequently degraded by the proteasome. Because O_2 is a substrate for HIF-PH2, hypoxia limits HIF-PH2 activity. This limitation is enhanced by the negative effect of hypoxia-driven mitochondrial reactive oxygen species (ROS) on HIF-PH2 function. Complex III in the mitochondrial electron transport chain (METC) receives two electrons from ubiquinone but can only transfer one electron at a time to cytochrome c (Cyt c). Complex III therefore transfers one electron to a quasi-stable ubisemiquinone radical. If this radical accumulates, O_2 that is dissolved in the mitochondrial membrane can capture the electron before cytochrome c accepts it, generating superoxide ($O_2^{\cdot-}$). If cellular O_2 is low, complex IV at the end of the METC is slow to transfer pairs of electrons to O_2 (making water), and the METC is blocked between complex III and IV, which favours the electron leak described above. The newly formed superoxide dismutates to H_2O_2. H_2O_2 can inhibit HIF-PH2 and oxidatively decarboxylate its cofactor, αKG. The resulting decrease in the hydroxylation of HIF1α and its subsequent proteasomal degradation supports HIF1α accumulation. Dashed arrows indicate the reactions that are slowed in hypoxia.

Chronic granulomatous disease
(CGD). An immunodeficiency state manifested by recurrent, often life-threatening, infections and the excessive formation of granulomas, caused by mutations in any one of four subunits of NADP oxidase 2.

PMNs migrate to sites of tissue damage in response to chemotactic factors such as interleukin-8 (IL-8), C5a, LTB4, and formyl peptides released by mitochondria or bacteria. All of these can trigger NOX2-dependent H_2O_2 production. It was shown in zebrafish larvae, where endothelial cells near wounded tissue activate the Nox isoform dual oxidase (Duox), that H_2O_2 itself is a chemotactic factor[65]. One mechanism through which H_2O_2 affects the migration of leukocytes in fish and humans involves the oxidative activation of the tyrosine kinase LYN and perhaps other SRC family kinases[66]. Thus, H_2O_2 might help to direct PMN movement in an autocrine or a paracrine manner.

Moreover, H_2O_2 that is produced in PMNs can contribute to PMN migration by promoting the accumulation of phosphatidylinositol-3,4,5-trisphosphate at the leading edge of the plasma membrane. NOX2 that is localized at the plasma membrane generates H_2O_2, which

transiently inactivates the phosphatase PTEN, allowing inositol polyphosphates to accumulate[33]. At the peak of a chemotactic gradient, where migrating PMNs congregate and begin to ingest bacteria, ROS levels are probably much higher and more sustained than near individual PMNs that are beginning to emigrate from the bloodstream. High ROS levels can suppress cell motility by promoting the accumulation of glutathionylated actin, which is impaired for polymerization[67]. Thus, ROS can coordinate the migration of PMNs towards the pathogens that wounding will probably introduce, and then ROS can promote the retention of the PMNs at that site.

Consistent with the potential role of NOX2 in the migration of mammalian PMNs, NOX2-deficient PMNs failed to migrate up a chemotactic gradient *in vitro* or to sites of inflammation *in vivo*[68]. Thus, the immunodeficiency of CGD not only involves defective bacterial killing, but might also be a result of delayed PMN accumulation. Therefore, it might seem paradoxical that CGD was named for the tendency to form excessive granulomas; however, this might reflect an impaired oxidative inactivation of chemotactic factors, such as C5a, formylated peptides and LTB4 (REFS 69,70). This indicates that ROS might help not only to initiate but also to terminate inflammation.

As mentioned above, host-derived factors, such as IL-8 and C5a, which are induced in response to bacterial products, can trigger ROS production from leukocytes. However, bacteria can also trigger ROS production directly through diverse types of receptors on leukocytes. For example, Toll-like receptor (TLR) engagement can induce ROS production by NOX2 and by other sources that contribute to signalling. NOX2-derived ROS were shown to be required for X-box-binding protein 1 (XBP1)-mediated transcriptional responses downstream of TLR2 and TLR4 that led to control of *Franciscella tularensis*[71]. In macrophages, TLR1, TLR2 and TRL4 engagement recruited mitochondria to phagosomes and promoted mitochondrial H_2O_2 production, which contributed to the control of *Salmonella enterica* subsp. *enterica* serovar Typhimurium infection *in vitro*. Mice expressing mitochondrial catalase had a twofold to threefold greater burden of *S.* Typhimurium 5 days after infection compared with wild-type mice[72]. However, it is not clear whether TLR-induced mitochondrial ROS are required for mice to clear infection.

ROS and inflammasomes. An important question in innate immunity is how structurally diverse agonists activate the same inflammasomes. ROS seem to mediate inflammasome activation in a range of circumstances, although the molecular steps involved and the sources of ROS remain controversial. The late Jurg Tschopp and his colleagues advanced a theory based on the premise that all known activators of the NOD-, LRR- and pyrin domain-containing 3 (NLRP3) inflammasome induce ROS, which lead to the dissociation of thioredoxin-interacting protein (TXNIP) from thioredoxin. They proposed that mitochondria are the source of ROS and that the association of TXNIP with NLRP3 is the basis of its activation[73]. Other work indicates that diverse

Figure 5 | **Regulation of transcription through DNA targeting by intranuclear ROS. a** | The induction of the transcription of the gene encoding vascular endothelial growth factor (VEGF) by hypoxia-inducible factor 1α (HIF1α) is enhanced through the dynein-mediated, perinuclear localization of mitochondria. Mitochondria-derived reactive oxygen species (ROS) diffuse into the nucleus, where they promote the oxidation of guanine nucleotides, forming 8-oxoguanine (8OG). **b** | Transcriptional regulation downstream of the activation of androgen receptors (ARs) or oestrogen receptors (ORs) and other nuclear receptors also involves DNA modifications by ROS. Engagement of ORs or ARs promotes the phosphorylation (P) of lysine-specific histone demethylase 1A (LSD1) by cAMP-dependent protein kinase (PKA). Active LSD1 not only demethylates histone 3 (H3) but also produces ROS, which then promote the formation of 8OG in the DNA. The altered DNA bases recruit base excision repair machinery, and the DNA breaks that are generated by 8OG DNA glycosylase 1 (OGG1) enable the activation of transcription by AR, OR and possibly also MYC.

Granulomas
Histological collections of macrophages, usually surrounded by lymphocytes and sometimes fibrocytes. Some of the macrophages might seem to be 'epithelioid' or fuse to become multinucleated giant cells. Granuloma formation is a chronic inflammatory response to various infectious and non-infectious agents.

NLRP3-activating stimuli might converge to promote mitochondrial damage. Damaged mitochondria produce excess ROS, which attack the mitochondrial DNA. Oxidized mitochondrial DNA enters the cytosol, and binds to and activates NLRP3 (REF. 74).

Further studies might help to clarify the links between diverse NRLP3-activating stimuli, mitochondrial damage and the resulting ROS overproduction. It is possible that another source of ROS might initiate the mitochondrial damage, in effect beginning a process that then becomes self-sustaining. This might explain why knock down of the common NOX2 subunit p22phox (also known as CY24A) decreased IL-1β secretion in response to a range of inflammasome activators[75]. It remains to be explained what terminates this process that risks initiating a positive feedback loop that could be lethal for the cell. In fact, production of mature IL-1β is closely associated with apoptosis[76].

ROS, the intestinal microbiota and enteric pathogens. In contrast to patients with CGD, mice that are only deficient in NOX2 are not susceptible to spontaneous infections during standard husbandry, which is similar to mice that are only deficient in inducible nitric oxide synthase (NOS2; also known as iNOS). However, mice lacking both NOX2 and NOS2 succumb to spontaneous, invasive infections by their own microbiota in the form of massive abscesses filled with PMNs and monocytes[77]. It seems that the antibiotic proteins and peptides, the acidification pumps, the lysosomal hydrolases and the autophagic mechanisms of PMNs and monocytes are not effective in the infected organs in the absence of both NOX2 and NOS2. This might indicate that both ROS and RNS are required to integrate with the other mechanisms listed above. Indeed, ROS are required for antibacterial autophagy in PMNs, macrophages and some epithelial cells[78]. The partial mutual redundancy

of NOX2 and NOS2 obscures the full importance of ROS in controlling infection. Taken together, these data show that NOX2 and NOS2 are essential for mice to coexist with their microbiota[77].

DUOX in colonic epithelial cells also contributes to coexistence of the host with the microbiota. This enzyme produces submicrobicidal levels of ROS in response to commensal bacteria, such as *Lactobacilli* spp., which promote epithelial repair and suppress inflammatory responses[79]. One mechanism of suppression of inflammation by ROS involves the reversible, oxidative inactivation of a component of the neddylation pathway, which prevents the ubiquitylation and the proteasomal degradation of inhibitor-α of NF-κB (IκBα) and the activation of NF-κB[80]. By contrast, high levels of ROS that are produced during intestinal inflammation, along with high levels of RNS, contribute not only to the suppression of microbial growth but also to epithelial injury[79].

Some intestinal pathogens capitalize on inflammatory ROS production. For example, ROS can convert endogenous thiosulphate into tetrathionate, which *S.* Typhimurium can use as an electron acceptor[81] to achieve a growth advantage in regions of the intestinal lumen that are nearly anoxic[79].

ROS and the regulation of lymphocyte function. ROS were discovered when phagocytosing leukocytes were found to consume large amounts of oxygen by a non-mitochondrial process (TIMELINE). B cells and T cells neither phagocytose nor show large increases in mitochondrial-independent oxygen consumption following activation. Thus, it was assumed that ROS have no role in adaptive immunity, and little notice was paid when superoxide production by the 'phagocyte oxidase' was discovered in transformed[82] and primary[83] human B cells at about one-tenth of the levels of ROS that are released by phagocytes. However, later studies showed that ROS production is functionally important in lymphocytes. Following B cell receptor (BCR) ligation, ROS transiently inactivate BCR-associated phosphatases and function synergistically with calcium transients to potentiate signal transduction[84]. Similarly, T cell receptor (TCR) engagement triggers ROS production, with superoxide and peroxide regulating pro-apoptotic and proliferative pathways, respectively[85]. NOX-derived ROS that are released outside of the plasma membrane or into the lumen of a plasma membrane-derived vesicle enter the T cell via aquaporin 3 to affect cytosolic phosphatases[86]. T cell-derived peroxide also activates NF-κB, which leads to the production of IL-2 (REF. 87). T cell activation also indirectly depends on ROS, in that the consumption of protons by NOX2 in the phagosomes of dendritic cells (DCs) retards phagosomal acidification, impedes the action of proteases and preserves peptides of sufficient length to be presented on MHC molecules[88].

Lymphocytes could not be cultured until Mishell and Dutton[89] discovered the trophic effect of supplementing the medium with the reducing agent 2-mercaptoethanol[89]. Using transformed lymphocytes, Nathan and Terry[90] showed that non-activated macrophages could replace the reducing agent to sustain lymphocyte

growth, but that activated, ROS-producing macrophages could not[90] (TIMELINE). Subsequent work established that macrophages and DCs can respond to various stimuli, including contact with antigen-specific T cells, by secreting glutathione, which is broken down to release cysteine, an amino acid that is otherwise scarce in extracellular fluid. Cysteine uptake allows the lymphocytes to synthesize their own glutathione, to maintain redox homestasis, and to undergo antigen-specific activation and proliferation[91]. Consistent with the observation that mouse macrophages differ in their secretion of lymphocyte-trophic thiols depending on their activation state[90], lamina propria-resident human macrophages secrete little cysteine, and neighbouring T cells are fairly glutathione-deficient and hyporeactive, whereas the lamina propria is infiltrated by innate immune cells with higher cysteine-releasing capacity during inflammatory bowel disease[92]. Moreover, regulatory T (T_{Reg}) cells can suppress glutathione release by DCs, thereby indirectly regulating the activation potential of other T cells[93].

As noted above, even though ROS help to mediate T cell activation, T cell activation also partly depends on help from accessory cells to maintain T cell levels of the antioxidant glutathione. This indicates that ROS can be immunosuppressive. Indeed, ROS were the first molecules found to suppress T cell function[94]. Some T_{Reg} cells can suppress other T cells through their release of ROS, and T_{Reg} cells can be induced by macrophage-derived ROS[95,96]. In keeping with these observations, T_{Reg} cells were found to be more resistant to ROS than effector T cells; their enhanced resistance was associated with greater secretion of thioredoxin[97].

Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells that are temporarily restricted from further differentiation. MDSC numbers can increase tenfold in the blood of patients with cancer and inflammatory disorders[98–100]. During cancer progression, the recruitment of MDSCs to the tumour site can suppress immune reactivity[101]. MDSCs produce large quantities of ROS. ROS production not only underlies the immunosuppressive properties of MDSCs but it is also thought to maintain them in an undifferentiated state[99,102]. Nitration of CD8, TCR, and CC-chemokine ligand 2 (CCL2) by MDSC-derived peroxynitrite prevents the binding of CD8+ T cells to peptide-loaded MHC class I, promotes antigen-specific tolerance and impairs cytotoxic T cell recruitment to tumours[101,103]. MDSCs from mice lacking NOX2 demonstrated little or no ROS production and they lacked the ability to suppress T cell proliferation and the production of IFNγ[101,103].

ROS and tumour cells. Once ROS were discovered to be a principal mechanism by which the immune system controls pathogens, investigators asked whether ROS also contribute to the ability of activated macrophages to selectively kill tumour cells. In several mouse models ROS seemed to account for much of the antitumour activity of immunologically activated macrophages[104–106]. Killing could be greatly increased by pharmacologically inhibiting tumour cell glutathione synthesis or

---

Neddylation
A process that is analogous to ubiquitylation, in which ubiquitin-like protein NEDD8 is conjugated to a protein substrate.

glutathione reductase, or by restricting dietary selenium, which is required for the function of glutathione peroxidase[107]. It was even possible to mimic activated macrophages with an artificial, particulate H_2O_2-generating system and to cure mice of an advanced lymphoma[108]. However, human cells proved to be about 100-fold more resistant to ROS than their mouse counterparts[109]. Moreover, cell lines derived from metastatic human tumours were found to produce ROS at high levels[110].

The phenomenon of ROS overproduction by tumour cells has been widely confirmed[111]. In some cases, excessive ROS production has been attributed to mutations in a mitochondrial gene that encodes a component of the mitochondrial electron transport chain. Introduction of those mutations into other tumour cells was sufficient to confer both enhanced ROS generation and ROS-dependent metastatic potential[112]. ROS release by tumour cells might sensitize, or even self-activate, their growth factor receptors by inhibiting the associated tyrosine phosphatases[51,113]. Tumour cell ROS production might also help to explain how tumour cells alter their central carbon metabolism[114] — for example, towards synthesis of nucleic acid precursors[23] — and it might also contribute to immunosuppression. Moreover, the mutagenic actions of ROS that are derived from inflammatory cells can contribute to the initial stages of tumorigenesis[115]. After a tumour is established, ROS derived from radiotherapy, from chemotherapy or from the tumour cells themselves might contribute to the genomic instability of tumour cells[116], fostering drug resistance, just as ROS production that is induced in bacteria by antibiotics can cause mutations that promote antibiotic resistance[117]. Finally, tumour cell-derived ROS can trigger the tumour stroma to produce angiogenic factors[111]. In contrast to more differentiated cancer cells, cancer stem cells exhibited lower levels of intracellular ROS, greater levels of antioxidant pathways and more efficient DNA repair responses to ionizing radiation[118–120]. Thus, the effects of ROS on tumours can range from tumour-promoting effects to tumour-destroying effects, which means that ROS-producing phagocytes are potentially dangerous cells for both the tumour and the host.

Looking ahead

Two sets of questions loom large over ROS biology: the mechanisms of ROS production and action, and the translational potential of this information in medicine.

Mechanistic mysteries. It remains unclear exactly how cytokines, TLR ligands, inflammasome agonists and lymphocyte antigen receptors trigger ROS production and how the subcellular localization, the magnitude and the duration of ROS production determine their specific functions. Systems biology has yet to integrate ROS biology fully into the 'wiring' diagrams that reflect our understanding of cellular behaviour.

These advances will partly depend on the development of tools that would help to identify ROS and their subcellular localization and to quantify them at the level of single cells and single molecular species in real time. These tools are beginning to be developed but

the challenges are considerable. Not all redox couples in a cell are maintained at the same equilibrium, and it is not well understood what insulates one couple from another. Some of the older organic dyes that react with ROS to produce or suppress fluorescence lack specificity for individual ROS[121]. Newer approaches that allow for sensitive and specific measurement of ROS include small compounds[122]; novel delivery systems, such as nanotubes[123] and peroxalate micelles[124]; and genetically encoded redox-sensitive fluorescent proteins, such as redox-oxidation-sensitive green fluorescent proteins (roGFPs)[125]. The use of some genetically encoded biosensors is limited by their slow or irreversible response to changing redox levels. However, roGFPs that are fused with glutaredoxin can capture real-time changes in the aspect of cellular redox potential that is linked to the redox state of glutathione[126]. Another challenge is to determine the extent of oxidation of specific targets, both per single molecule and as a proportion of the molecules of a given molecular species. Quantitative redox proteomic techniques are struggling with this challenge[121].

Medical advances. The disappointing history of efforts to prevent or to treat disease with exogenous antioxidants does not reflect the important role of ROS in pharmacology. Many drugs partly work by generating ROS, by inducing intracellular production of ROS, by sensitizing cells to ROS[107], by diminishing the cellular production of ROS or by increasing the catabolism of ROS[111,127,128].

For example, many antibiotics kill bacteria partly by inducing them to make ROS. β-lactams, which target peptidoglycan synthesis in the bacterial cell wall, and aminoglycosides, which inhibit the bacterial ribosome, both create metabolic stress that results in NADH auto-oxidation and $O_2^{\bullet-}$ production in bacteria. $O_2^{\bullet-}$ can dislodge Fe^{2+} from iron–sulphur clusters, and Fe^{2+} together with $O_2^{\bullet-}$ or H_2O_2 can generate the most potent oxidant known, $OH^{\bullet}$, which contributes to bacterial death[129,130]. In short, a principal biochemical mechanism of host defence that evolved in the immune system over millions of years matches a major form of artificial host defence that was engineered by scientists over the past few decades. This is not a coincidence; it is a consequence of convergent evolution. Most antibiotics in clinical use are, or mimic, natural microbial products — signalling molecules that microorganisms use to communicate with each other. Apparently, similar advantages in fitness against microbial competitors supported the evolution of small, secreted, ROS-inducing molecules in bacteria and large, ROS-generating intracellular enzymes in eukaryotes. A better understanding of how antibiotics lead to ROS production as part of their mechanism of action[129] could help the urgent need to revitalize antibiotic research and discovery[131].

Some anti-infectives, such as clofazimine[151], and anticancer agents that also have antibiotic actions, such as adriamycin[152] and bleomycin[153], produce ROS directly. In the case of the anticancer agents, ROS production contributes both to their efficacy and to their toxicity.

Among the unanticipated anti-inflammatory actions of statins is their ability to decrease ROS production by endothelial cells. The synthetic oleanoid triterpenoids, one of the newest classes of anti-inflammatory agents, partly work by binding to KEAP1 (Kelch-like ECH-associated protein 1), which releases nuclear-related factor 2 (NRF2; also known as NF2L2) to induce a panoply of endogenous antioxidant defences[132].

Substantial medical advances could result from an increased understanding of how to foster or to inhibit ROS production, and how to monitor the effects of these interventions.

Note added in proof

Two recent reports[154,155] demonstrated that killing of *Escherichia coli* by norfloxacin, ofloxacin, kanamycin or ampicillin does not involve ROS.

1. Nathan, C. & Ding, A. Snapshot: reactive oxygen intermediates (ROI). *Cell* **140**, 951–951.e2 (2010).
2. Nishida, M. *et al.* Hydrogen sulfide anion regulates redox signaling via electrophile sulfhydration. *Nature Chem. Biol.* **8**, 714–724 (2012).
3. Finkel, T. From sulfenylation to sulfhydration: what a thiolate needs to tolerate. *Sci. Signal.* **5**, pe10 (2012).
4. Paul, B. D. & Snyder, S. H. H_2S signalling through protein sulfhydration and beyond. *Nature Rev. Mol. Cell. Biol.* **13**, 499–507 (2012).
5. Wink, D. A. *et al.* Nitric oxide and redox mechanisms in the immune response. *J. Leuk. Biol.* **89**, 873–891 (2011).
6. Steinhubl, S. R. Why have antioxidants failed in clinical trials? *Am. J. Cardiol.* **101**, 14D–19D (2008).
7. Brennan, M. L. & Hazen, S. L. Emerging role of myeloperoxidase and oxidant stress markers in cardiovascular risk assessment. *Curr. Opin. Lipidol.* **14**, 353–359 (2003).
8. Bae, Y. S., Oh, H., Rhee, S. G. & Yoo, Y. D. Regulation of reactive oxygen species generation in cell signaling. *Mol. Cells* **32**, 491–509 (2011).
9. Finkel, T. Signal transduction by mitochondrial oxidants. *J. Biol. Chem.* **287**, 4434–4440 (2012).
10. Jiang, F., Zhang, Y. & Dusting, G. J. NADPH oxidase-mediated redox signaling: roles in cellular stress response, stress tolerance, and tissue repair. *Pharmacol. Rev.* **63**, 218–242 (2011).
11. Lambeth, J. D. NOX enzymes and the biology of reactive oxygen. *Nature Rev. Immunol.* **4**, 181–189 (2004).
12. Aguirre, J. & Lambeth, J. D. Nox enzymes from fungus to fly to fish and what they tell us about Nox function in mammals. *Free Radic. Biol. Med.* **49**, 1342–1353 (2010).
13. Imlay, J. A. Cellular defenses against superoxide and hydrogen peroxide. *Annu. Rev. Biochem.* **77**, 755–776 (2008).
14. Yazdanpanah, B. *et al.* Riboflavin kinase couples TNF receptor 1 to NADPH oxidase. *Nature* **460**, 1159–1163 (2009).
15. Mailloux, R. J. & Harper, M. E. Uncoupling proteins and the control of mitochondrial reactive oxygen species production. *Free Radic. Biol. Med.* **51**, 1106–1115 (2011).
16. Corzo, C. A. *et al.* Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. *J. Immunol.* **182**, 5693–5701 (2009).
17. Radi, R., Beckman, J. S., Bush, K. M. & Freeman, B. A. Peroxynitrite oxidation of sulfhydryls. The cytotoxic potential of superoxide and nitric oxide. *J. Biol. Chem.* **266**, 4244–4250 (1991).
18. Gonzalez-Nieto, D. *et al.* Connexin-43 in the osteogenic BM niche regulates its cellular composition and the bidirectional traffic of hematopoietic stem cells and progenitors. *Blood* **119**, 5144–5154 (2012).
19. Holmgren, A. & Lu, J. Thioredoxin and thioredoxin reductase: current research with special reference to human disease. *Biochem. Biophys. Res. Commun.* **396**, 120–124 (2010).
20. Weissbach, H. *et al.* Peptide methionine sulfoxide reductase: structure, mechanism of action, and biological function. *Arch. Biochem. Biophys.* **397**, 172–178 (2002).
21. Bryk, R., Griffin, P. & Nathan, C. Peroxynitrite reductase activity of bacterial peroxiredoxins. *Nature* **407**, 211–215 (2000).
22. Morgan, B. *et al.* Multiple glutathione disulfide removal pathways mediate cytosolic redox homeostasis. *Nature Chem. Biol.* **9**, 119–125 (2012).

23. Anastasiou, D. *et al.* Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses. *Science* **334**, 1278–1283 (2011).
24. O'Donnell-Tormey, J., Nathan, C. F., Lanks, K., DeBoer, C. J. & de la Harpe, J. Secretion of pyruvate. An antioxidant defense of mammalian cells. *J. Exp. Med.* **165**, 500–514 (1987).
25. Bertini, R. *et al.* Thioredoxin, a redox enzyme released in infection and inflammation, is a unique chemoattractant for neutrophils, monocytes, and T cells. *J. Exp. Med.* **189**, 1783–1789 (1999).
26. Shichita, T. *et al.* Peroxiredoxin family proteins are key initiators of post-ischemic inflammation in the brain. *Nature Med.* **18**, 911–917 (2012).
27. Seifert, U. *et al.* Immunoproteasomes preserve protein homeostasis upon interferon-induced oxidative stress. *Cell* **142**, 613–624 (2010).
28. Scherz-Shouval, R. & Elazar, Z. Regulation of autophagy by ROS: physiology and pathology. *Trends Biochem. Sci.* **36**, 30–38 (2011).
29. Thorpe, G. W., Fong, C. S., Alic, N., Higgins, V. J. & Dawes, I. W. Cells have distinct mechanisms to maintain protection against different reactive oxygen species: oxidative-stress-response genes. *Proc. Natl Acad. Sci. USA* **101**, 6564–6569 (2004).
30. Nathan, C. Specificity of a third kind: reactive oxygen and nitrogen intermediates in cell signaling. *J. Clin. Invest.* **111**, 769–778 (2003).
31. Ferrer-Sueta, G. *et al.* Factors affecting protein thiol reactivity and specificity in peroxide reduction. *Chem. Res. Toxicol.* **24**, 434–450 (2011).
32. Winterbourn, C. C. & Hampton, M. B. Thiol chemistry and specificity in redox signaling. *Free Radic. Biol. Med.* **45**, 549–561 (2008).
33. Kuiper, J. W., Sun, C., Magalhaes, M. A. & Glogauer, M. Rac regulates $PtdInsP_3$ signaling and the chemotactic compass through a redox-mediated feedback loop. *Blood* **118**, 6164–6171 (2011).
34. Paulsen, C. E. *et al.* Peroxide-dependent sulfenylation of the EGFR catalytic site enhances kinase activity. *Nature Chem. Biol.* **8**, 57–64 (2012).
35. Wani, R. *et al.* Isoform-specific regulation of Akt by PDGF-induced reactive oxygen species. *Proc. Natl Acad. Sci. USA* **108**, 10550–10555 (2011).
36. Guo, Z., Kozlov, S., Lavin, M. F., Person, M. D. & Paull, T. T. ATM activation by oxidative stress. *Science* **330**, 517–521 (2010).
37. Erickson, J. R. *et al.* A dynamic pathway for calcium-independent activation of CaMKII by methionine oxidation. *Cell* **133**, 462–474 (2008).
38. Burgoyne, J. R. *et al.* Cysteine redox sensor in PKGIa enables oxidant-induced activation. *Science* **317**, 1393–1397 (2007).
39. Kroncke, K. D. & Klotz, L. O. Zinc fingers as biologic redox switches? *Antioxid. Redox Signal.* **11**, 1015–1027 (2009).
40. de Keizer, P. L., Burgering, B. M. & Dansen, T. B. Forkhead box O as a sensor, mediator, and regulator of redox signaling. *Antioxid. Redox Signal.* **14**, 1093–1106 (2011).
41. Wang, Y., Yang, J. & Yi, J. Redox sensing by proteins: oxidative modifications on cysteines and the consequent events. *Antioxid. Redox Signal.* **16**, 649–657 (2012).
42. Fu, X., Kassim, S. Y., Parks, W. C. & Heinecke, J. W. Hypochlorous acid oxygenates the cysteine switch domain of pro-matrilysin (MMP-7). A mechanism for matrix metalloproteinase activation and atherosclerotic plaque rupture by myeloperoxidase. *J. Biol. Chem.* **276**, 41279–41287 (2001).
43. Taggart, C. *et al.* Oxidation of either methionine 351 or methionine 358 in α_1-antitrypsin causes loss of anti-neutrophil elastase activity. *J. Biol. Chem.* **275**, 27258–27265 (2000).

44. Reddy, V. Y. *et al.* Oxidative dissociation of human α_2-macroglobulin tetramers into dysfunctional dimers. *J. Biol. Chem.* **269**, 4683–4691 (1994).
45. Carp, H. & Janoff, A. Inactivation of bronchial mucous proteinase inhibitor by cigarette smoke and phagocyte-derived oxidants. *Exp. Lung Res.* **1**, 225–237 (1980).
46. Lando, D., Peet, D. J., Whelan, D. A., Gorman, J. J. & Whitelaw, M. L. Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. *Science* **295**, 858–861 (2002).
47. Doucette, C. D. Schwab, D.J., Wingreen, N.S. & Rabinowitz, J.D. α-Ketoglutarate coordinates carbon and nitrogen utilization via enzyme I inhibition. *Nature Chem. Biol.* **7**, 894–901 (2011).
48. Leichert, L. I. & Jakob, U. Protein thiol modifications visualized *in vivo*. *PLoS Biol.* **2**, e333 (2004).
49. White, A. A., Crawford, K. M., Patt, C. S. & Lad, P. J. Activation of soluble guanylate cyclase from rat lung by incubation or by hydrogen peroxide. *J. Biol. Chem.* **251**, 7304–7312 (1976).
50. Feng, W., Liu, G., Allen, P. D. & Pessah, I. N. Transmembrane redox sensor of ryanodine receptor complex. *J. Biol. Chem.* **275**, 35902–35907 (2000).
51. Karisch, R. *et al.* Global proteomic assessment of the classical protein-tyrosine phosphatome and "Redoxome". *Cell* **146**, 826–840 (2011).
52. Finkel, T. Signal transduction by reactive oxygen species. *J. Cell Biol.* **194**, 7–15 (2011).
53. Cosentino, C., Grieco, D. & Costanzo, V. ATM activates the pentose phosphate pathway promoting anti-oxidant defence and DNA repair. *EMBO J.* **30**, 546–555 (2011).
54. Ito, K. *et al.* Reactive oxygen species act through p38 MAPK to limit the lifespan of hematopoietic stem cells. *Nature Med.* **12**, 446–451 (2006).
55. Okuno, Y., Nakamura-Ishizu, A., Otsu, K., Suda, T. & Kubota, Y. Pathological neoangiogenesis depends on oxidative stress regulation by ATM. *Nature Med.* **18**, 1208–1216 (2012).
56. Storz, G., Tartaglia, L. A. & Ames, B. N. Transcriptional regulator of oxidative stress-inducible genes: direct activation by oxidation. *Science* **248**, 189–194 (1990).
57. Brunelle, J. K. *et al.* Oxygen sensing requires mitochondrial ROS but not oxidative phosphorylation. *Cell. Metab.* **1**, 409–414 (2005).
58. Guzy, R. D. *et al.* Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing. *Cell. Metab.* **1**, 401–408 (2005).
59. Mansfield, K. D. *et al.* Mitochondrial dysfunction resulting from loss of cytochrome *c* impairs cellular oxygen sensing and hypoxic HIF-α activation. *Cell. Metab.* **1**, 393–399 (2005).
60. Ruchko, M. V. *et al.* Hypoxia-induced oxidative base modifications in the VEGF hypoxia-response element are associated with transcriptionally active nucleosomes. *Free Radic. Biol. Med.* **46**, 352–359 (2009).
61. Al-Mehdi, A. B. *et al.* Perinuclear mitochondrial clustering creates an oxidant-rich nuclear domain required for hypoxia-induced transcription. *Sci. Signal.* **5**, ra47 (2012).
62. Ju, B. G. *et al.* A topoisomerase IIβ-mediated dsDNA break required for regulated transcription. *Science* **312**, 1798–1802 (2006).
63. Perillo, B. *et al.* DNA oxidation as triggered by H3K9me2 demethylation drives estrogen-induced gene expression. *Science* **319**, 202–206 (2008).
64. Amente, S., Lania, L., Avvedimento, E. V. & Majello, B. DNA oxidation drives Myc mediated transcription. *Cell Cycle* **9**, 3002–3004 (2010).
65. Niethammer, P., Grabher, C., Look, A. T. & Mitchison, T. J. A tissue-scale gradient of hydrogen peroxide mediates rapid wound detection in zebrafish. *Nature* **459**, 996–999 (2009).

66. Yoo, S. K., Starnes, T. W., Deng, Q. & Huttenlocher, A. Lyn is a redox sensor that mediates leukocyte wound attraction in vivo. *Nature* **480**, 109–112 (2011).

67. Sakai, D. et al. Remodeling of actin cytoskeleton in mouse periosteal cells under mechanical loading induces periosteal cell proliferation during bone formation. *PLoS ONE* **6**, e24847 (2011).

68. Hattori, H. et al. Small-molecule screen identifies reactive oxygen species as key regulators of neutrophil chemotaxis. *Proc. Natl Acad. Sci. USA* **107**, 3546–3551 (2010).

69. Henderson, W. R. & Klebanoff, S. J. Leukotriene production and inactivation by normal, chronic granulomatous disease and myeloperoxidase-deficient neutrophils. *J. Biol. Chem.* **258**, 13522–13527 (1983).

70. Segal, B. H., Kuhns, D. B., Ding, L., Gallin, J. I. & Holland, S. M. Thioglycollate peritonitis in mice lacking C5, 5-lipoxygenase, or p47phox: complement, leukotrienes, and reactive oxidants in acute inflammation. *J. Leukoc. Biol.* **71**, 410–416 (2002).

71. Martinon, F., Chen, X., Lee, A. H. & Glimcher, L. H. TLR activation of the transcription factor XBP1 regulates innate immune responses in macrophages. *Nature Immunol.* **11**, 411–418 (2010).

72. West, A. P. et al. TLR signalling augments macrophage bactericidal activity through mitochondrial ROS. *Nature* **472**, 476–480 (2011).

73. Zhou, R., Yazdi, A. S., Menu, P. & Tschopp, J. A role for mitochondria in NLRP3 inflammasome activation. *Nature* **469**, 221–225 (2011).

74. Shimada, K. et al. Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis. *Immunity* **36**, 401–414 (2012).

75. Dostert, C. et al. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. *Science* **320**, 674–677 (2008).

76. Hogquist, K. A., Nett, M. A., Unanue, E. R. & Chaplin, D. D. Interleukin 1 is processed and released during apoptosis. *Proc. Natl Acad. Sci. USA* **88**, 8485–8489 (1991).

77. Shiloh, M. U. et al. Phenotype of mice and macrophages deficient in both phagocyte oxidase and inducible nitric oxide synthase. *Immunity* **10**, 29–38 (1999).

78. Huang, J. et al. Activation of antibacterial autophagy by NADPH oxidases. *Proc. Natl Acad. Sci. USA* **106**, 6226–6231 (2009).

79. Espey, M. G. Role of oxygen gradients in shaping redox relationships between the human intestine and its microbiota. *Free Radic. Biol. Med.* **55**, 130–140 (2013).

80. Kumar, A. et al. Commensal bacteria modulate cullin-dependent signaling via generation of reactive oxygen species. *EMBO J.* **26**, 4457–4466 (2007).

81. Winter, S. E. et al. Gut inflammation provides a respiratory electron acceptor for Salmonella. *Nature* **467**, 426–429 (2010).

82. Maly, F. E. et al. The superoxide generating system of B cell lines. Structural homology with the phagocytic oxidase and triggering via surface Ig. *J. Immunol.* **140**, 2334–2339 (1988).

83. Maly, F. E. et al. Superoxide-dependent nitroblue tetrazolium reduction and expression of cytochrome b-245 components by human tonsillar B lymphocytes and B cell lines. *J. Immunol.* **142**, 1260–1267 (1989).

84. Singh, D. K. et al. The strength of receptor signaling is centrally controlled through a cooperative loop between Ca²⁺ and an oxidant signal. *Cell* **121**, 281–293 (2005).

85. Devadas, S., Zaritskaya, L., Rhee, S. G., Oberley, L. & Williams, M. S. Discrete generation of superoxide and hydrogen peroxide by T cell receptor stimulation: selective regulation of mitogen-activated protein kinase activation and fas ligand expression. *J. Exp. Med.* **195**, 59–70 (2002).

86. Hara-Chikuma, M. et al. Chemokine-dependent T cell migration requires aquaporin-3-mediated hydrogen peroxide uptake. *J. Exp. Med.* **209** 1743–1752 (2012).

87. Los, M. et al. IL-2 gene expression and NF-kappa B activation through CD28 requires reactive oxygen production by 5-lipoxygenase. *EMBO J.* **14**, 3731–3740 (1995).

88. Savina, A. et al. NOX2 controls phagosomal pH to regulate antigen processing during crosspresentation by dendritic cells. *Cell* **126**, 205–218 (2006).

89. Mishell, R. I. & Dutton, R. W. Immunization of normal mouse spleen cell suspensions in vitro. *Science* **153**, 1004–1006 (1966).

90. Nathan, C. F & Terry, W. D. Differential stimulation of murine lymphoma growth in vitro by normal and BCG-activated macrophages. *J. Exp. Med.* **142**, 887–902 (1975).

91. Angelini, G. et al. Antigen-presenting dendritic cells provide the reducing extracellular microenvironment required for T lymphocyte activation. *Proc. Natl Acad. Sci. USA* **99**, 1491–1496 (2002).

92. Sido, B. et al. A prominent role for mucosal cystine/cysteine metabolism in intestinal immunoregulation. *Gastroenterology* **134**, 179–191 (2008).

93. Yan, Z., Garg, S. K., Kipnis, J. & Banerjee, R. Extracellular redox modulation by regulatory T cells. *Nature Chem. Biol.* **5**, 721–723 (2009).

94. Fisher, R. I. & Bostick-Bruton, F. Depressed T cell proliferative responses in Hodgkin's disease: role of monocyte-mediated suppression via prostaglandins and hydrogen peroxide. *J. Immunol.* **129**, 1770–1774 (1982).

95. Efimova, O., Szankasi, P. & Kelley, T. W. Ncf1 (p47phox) is essential for direct regulatory T cell mediated suppression of CD4 + effector T cells. *PLoS ONE* **6**, e16013 (2011).

96. Gelderman, K. A., Hultqvist, M., Holmberg, J., Olofsson, P. & Holmdahl, R. T cell surface redox levels determine T cell reactivity and arthritis susceptibility. *Proc. Natl Acad. Sci. USA* **103**, 12831–12836 (2006).

97. Mougiakakos, D., Johansson, C. C., Jitschin, R., Bottcher, M. & Kiessling, R. Increased thioredoxin-1 production in human naturally occurring regulatory T cells confers enhanced tolerance to oxidative stress. *Blood* **117**, 857–861 (2011).

98. Colombo, M. P. & Piconese, S. Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy. *Nature Rev. Cancer* **7**, 880–887 (2007).

99. Gabrilovich, D. I. & Nagaraj, S. Myeloid-derived suppressor cells as regulators of the immune system. *Nature Rev. Immunol.* **9**, 162–174 (2009).

100. Muhlebach, T. J. et al. Treatment of patients with chronic granulomatous disease with recombinant human interferon-gamma does not improve neutrophil oxidative metabolism, cytochrome b558 content or levels of four anti-microbial proteins. *Clin. Exp. Immunol.* **88**, 203–206 (1992).

101. Nagaraj, S. et al. Altered recognition of antigen is a mechanism of CD8⁺ T cell tolerance in cancer. *Nature Med.* **13**, 828–835 (2007).

102. Kusmartsev, S. & Gabrilovich, D. I. Inhibition of myeloid cell differentiation in cancer: the role of reactive oxygen species. *J. Leuk. Biol.* **74**, 186–196 (2003).

103. Molon, B. et al. Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. *J. Exp. Med.* **208**, 1949–1962 (2011).

104. Nathan, C. & Cohn, Z. Role of oxygen-dependent mechanisms in antibody-induced lysis of tumor cells by activated macrophages. *J. Exp. Med.* **152**, 198–208 (1980).

105. Nathan, C. F. & Klebanoff, S. J. Augmentation of spontaneous macrophage-mediated cytolysis by eosinophil peroxidase. *J. Exp. Med.* **155**, 1291–1308 (1982).

106. Nathan, C. F., Silverstein, S. C., Brukner, L. H. & Cohn, Z. A. Extracellular cytolysis by activated macrophages and granulocytes. II. Hydrogen peroxide as a mediator of cytotoxicity. *J. Exp. Med.* **149**, 100–113 (1979).

107. Nathan, C. F., Arrick, B. A., Murray, H. W., DeSantis, N. M. & Cohn, Z. A. Tumor cell anti-oxidant defenses. Inhibition of the glutathione redox cycle enhances macrophage-mediated cytolysis. *J. Exp. Med.* **153**, 766–782 (1981).

108. Nathan, C. F. & Cohn, Z. A. Antitumor effects of hydrogen peroxide in vivo. *J. Exp. Med.* **154**, 1539–1553 (1981).

109. O'Donnell-Tormey, J., DeBoer, C. J. & Nathan, C. F. Resistance of human tumor cells in vitro to oxidative cytolysis. *J. Clin. Invest.* **76**, 80–86 (1985).

110. Szatrowski, T. P. & Nathan, C. F. Production of large amounts of hydrogen peroxide by human tumor cells. *Cancer Res.* **51**, 794–798 (1991).

111. Liou, G. Y. & Storz, P. Reactive oxygen species in cancer. *Free Radic. Res.* **44**, 479–496 (2010).

112. Ishikawa, K. et al. ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis. *Science* **320**, 661–664 (2008).

113. Tonks, N. K. Redox redux: revisiting PTPs and the control of cell signaling. *Cell* **121**, 667–670 (2005).

114. Ward, P. S. & Thompson, C. B. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. *Cancer Cell* **21**, 297–308 (2012).

115. Weitzman, S. A., Weitberg, A. B., Clark, E. P. & Stossel, T. P. Phagocytes as carcinogens: malignant transformation produced by human neutrophils. *Science* **227**, 1231–1233 (1985).

116. Lonkar, P. & Dedon, P. C. Reactive species and DNA damage in chronic inflammation: reconciling chemical mechanisms and biological fates. *Int. J. Cancer* **128**, 1999–2009 (2011).

117. Kohanski, M. A., DePristo, M. A. & Collins, J. J. Sublethal antibiotic treatment leads to multidrug resistance via radical-induced mutagenesis. *Mol. Cell* **37**, 311–320 (2010).

118. Ishimoto, T. et al. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc⁻ and thereby promotes tumor growth. *Cancer Cell* **19**, 387–400 (2011).

119. Gilbertson, R. J. & Rich, J. N. Making a tumour's bed: glioblastoma stem cells and the vascular niche. *Nature Rev. Cancer* **7**, 733–736 (2007).

120. Diehn, M. et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. *Nature* **458**, 780–783 (2009).

121. Knoefler, D. et al. Quantitative in vivo redox sensors uncover oxidative stress as an early event in life. *Mol. Cell* **47**, 767–776 (2012).

122. Gomes, A., Fernandes, E. & Lima, J. L. Fluorescence probes used for detection of reactive oxygen species. *J. Biochem. Biophys. Methods* **65**, 45–80 (2005).

123. Kim, J. H. et al. Single-molecule detection of H_2O_2 mediating angiogenic redox signaling on fluorescent single-walled carbon nanotube array. *ACS Nano* **5**, 7848–7857 (2011).

124. Lee, D. et al. Detection of hydrogen peroxide with chemiluminescent micelles. *Int. J. Nanomed.* **3**, 471–476 (2008).

125. Belousov, V. V. et al. Genetically encoded fluorescent indicator for intracellular hydrogen peroxide. *Nature Methods* **3**, 281–286 (2006).

126. Gutscher, M. et al. Real-time imaging of the intracellular glutathione redox potential. *Nature Methods* **5**, 553–559 (2008).

127. Raj, L. et al. Selective killing of cancer cells by a small molecule targeting the stress response to ROS. *Nature* **475**, 231–234 (2011).

128. Trachootham, D., Alexandre, J. & Huang, P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? *Nature Rev. Drug Discov.* **8**, 579–591 (2009).

129. Kohanski, M. A., Dwyer, D. J., Hayete, B., Lawrence, C. A. & Collins, J. J. A common mechanism of cellular death induced by bactericidal antibiotics. *Cell* **130**, 797–810 (2007).

130. Foti, J. J., Devadoss, B., Winkler, J. A., Collins, J. J. & Walker, G. C. Oxidation of the guanine nucleotide pool underlies cell death by bactericidal antibiotics. *Science* **336**, 315–319 (2012).

131. Nathan, C. Fresh approaches to anti-infective therapies. *Sci. Transl. Med.* **4**, 140sr2 (2012).

132. Liby, K. T. & Sporn, M. B. Synthetic oleanane triterpenoids: multifunctional drugs with a broad range of applications for prevention and treatment of chronic disease. *Pharmacol. Rev.* **64**, 972–1003 (2012).

133. Pineda-Molina, E. et al. Glutathionylation of the p50 subunit of NF-κB: a mechanism for redox-induced inhibition of DNA binding. *Biochemistry* **40**, 14134–14142 (2001).

134. Warburg, O. Beobachtungen über die Oxydationsprozesse im Seeigelei. *Z. Physiol. Chem.* **57**, 1–16 (1908).

135. Bentley, R. in *The Enzymes* 2nd edn Vol. 27 Ch. 24 (eds Boyer, P. D., Lardy, H. & Myrbäck, K.) 567–586 (Academic, 1963).

136. Wilson, R. & Turner, A. P. F. Glucose oxidase: an ideal enzyme. *Biosensors & Bioelectronics* **7**, 165–185 (1992).

137. Sbarra, A. J. & Karnovsky, M. L. The biochemical basis of phagocytosis. I. Metabolic changes during the ingestion of particles by polymorphonuclear leukocytes. *J. Biol. Chem.* **234**, 1355–1362 (1959).

138. Iyer, G. Y. N., Islam, M. F. & Quastel, J. H. Biochemical aspects of phagocytosis. *Nature* **192**, 535–541 (1961).

139. McCord, J. M. & Fridovich, I. Superoxide dismutase. An enzymic function for erythrocuprein (hemocuprein). *J. Biol. Chem.* **244**, 6049–6055 (1969).

140. Babior, B. M., Kipnes, R. S. & Curnutte, J. T. Biological defense mechanisms. The production by leukocytes of superoxide, a potential bactericidal agent. *J. Clin. Invest.* **52**, 741–744 (1973).

141. Curnutte, J. T., Whitten, D. M. & Babior, B. M. Defective superoxide production by granulocytes from patients with chronic granulomatous disease. *N. Engl. J. Med.* **290**, 593–597 (1974).

142. Nathan, C. F. & Root, R. K. Hydrogen peroxide release from mouse peritoneal macrophages: dependence on sequential activation and triggering. *J. Exp. Med.* **146**, 1648–1662 (1977).

143. Foerder, C. A., Klebanoff, S. J. & Shapiro, B. M. Hydrogen peroxide production, chemiluminescence, and the respiratory burst of fertilization: interrelated events in early sea urchin development. *Proc. Natl Acad. Sci. USA* **75**, 3183–3187 (1978).

144. Segal, A. W. & Jones, O. T. Novel cytochrome *b* system in phagocytic vacuoles of human granulocytes. *Nature* **276**, 515–517 (1978).

145. Klebanoff, S. J. Oxygen metabolism and the toxic properties of phagocytes. *Ann. Intern. Med.* **93**, 480–489 (1980).

146. Nathan, C. F., Murray, H. W., Wiebe, M. E. & Rubin, B. Y. Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. *J. Exp. Med.* **158**, 670–689 (1983).

147. Nathan, C. F. *et al.* Local and systemic effects of intradermal recombinant interferon-γ in patients with lepromatous leprosy. *N. Engl. J. Med.* **315**, 6–15 (1986).

148. Royer-Pokora, B. *et al.* Cloning the gene for an inherited human disorder — chronic granulomatous disease — on the basis of its chromosomal location. *Nature* **322**, 32–38 (1986).

149. Ezekowitz, R. A., Dinauer, M. C., Jaffe, H. S., Orkin, S. H. & Newburger, P. E. Partial correction of the phagocyte defect in patients with X-linked chronic granulomatous disease by subcutaneous interferon gamma. *N. Engl. J. Med.* **319**, 146–151 (1988).

150. Suh, Y. A. *et al.* Cell transformation by the superoxide-generating oxidase Mox1. *Nature* **401**, 79–82 (1999).

151. Grant, S. S., Kaufmann, B. B., Chand, N. S., Haseley, N. & Hung, D. T. Eradication of bacterial persisters with antibiotic-generated hydroxyl radicals. *Proc. Natl Acad. Sci. USA* **109**, 12147–12152 (2012).

152. Doroshow, J. H. & Davies, K. J. Comparative cardiac oxygen radical metabolism by anthracycline antibiotics, mitoxantrone, bisantrene, 4'-(9-acridinylamino)-methanesulfon-m-anisidide, and neocarzinostatin. *Biochem. Pharmacol.* **32**, 2935–2939 (1983).

153. Dorr, R.T. Bleomycin pharmacology: mechanism of action and resistance, and clinical pharmacokinetics. *Semin. Oncol.* **19**, 3–8 (1992).

154. Liu, Y. & Imlay, J. A. Cell death from antibiotics without the involvement of reactive oxygen species. *Science* **339**, 1210 (2013).

155. Keren, I., Wu, Y., Inocencio, U., Mulcahy, L. R. & Lewis, K. Killing by bactericidal antibiotics does not depend on reactive oxygen species. *Science* **339**, 1213 (2013).

Competing interests statement
The authors declare no competing financial interests.

FURTHER INFORMATION
Carl Nathan's homepage:
http://weill.cornell.edu/research/cnathan/

ALL LINKS ARE ACTIVE IN THE ONLINE PDF